Gallium Ga 68-DOTA-FAPI-04

Phase 1Radiopharmaceutical

UUniversity of Michigan Rogel Cancer Center

Gallium Ga 68-DOTA-FAPI-04 is one of 8 small molecule programs targeting Neuroendocrine Tumor. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Neuroendocrine TumorRecruiting

Neuroendocrine TumorPhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Neuroendocrine Tumor

#DrugCompanyPhaseTrials

Lutathera

AAdvanced Accelerator Applications

Approved

1 2

Avastin

Roche

Phase 3

1 3

Sandostatin

Sun Pharmaceutical Industries, Inc.

Phase 3

1 4

Votrient

Novartis

Phase 2

1 5

Recombinant Human GM-CSF

EEastern Cooperative Oncology Group

Phase 3

1 6

Recombinant Interferon Alfa-2b

SSt. Jude Children's Research Hospital

Phase 3

1 7

Alphamedix

OOrano Med LLC

Phase 2

1 8

Gallium Ga 68-DOTA-FAPI-04

UUniversity of Michigan Rogel Cancer Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 1Recruiting

Neuroendocrine Tumor

NCT07132645

Clinical

Trials by Indication[1]

Neuroendocrine Tumor1 trial

An Exploratory Study of [68Ga]Ga-Fibroblast Activation Protein Inhibitor 4 ([68Ga]Ga-FAPI-04) in Patients With High-Grade Neuroendocrine Neoplasms

Recruiting·UUniversity of Michigan Rogel Cancer Center·Phase 1·NCT07132645·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Gallium Ga 68-DOTA-FAPI-04. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Gallium Ga 68-DOTA-FAPI-04 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Gallium Ga 68-DOTA-FAPI-04. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Michigan Rogel Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Radiopharmaceutical[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Michigan Rogel Cancer Center

Gallium Ga 68-DOTA-FAPI-04

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Neuroendocrine Tumor1 trial

References

Drug Info

Quick Facts

Related News